Akeso's Ivonescimab Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Non-Small-Cell Lung Carcinoma
Shots:
- The NMPA has granted BTD for AK112 (PD-1/VEGF bispecific Ab) + docetaxel to treat patients with LA or metastatic NSCLC patients who failed to respond to prior PD-(L)1 inhibitor combined with Pt-based doublet CT
- In recent studies, AK112 showed a favorable safety profile and promising anti-tumor efficacy. Additionally, the therapy has the potential to offer NSCLC patients a useful alternative for overcoming Ab therapy immunotherapy resistance
- The company is currently conducting a P-III clinical trial of AK112 monothx. for NSCLC patients with positive PD-L1 expression & P-III trial of AK112 for the treatment of EGFR mutated advanced non-sq. NSCLC
Ref: PRNewswire | Image: Akeso
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
